Recent Press Releases

Abbott's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe

- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified


Abbott Announces Increase in Quarterly Dividend

Abbott Declares 364th Consecutive Quarterly Dividend


CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals

Abbott Completes Acquisition of Veropharm

ABBOTT PARK, Ill., Dec. 12, 2014 /PRNewswire/ -- Abbott (ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence...

FDA Drug Safety Communication: FDA reporting mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reactions

The U.S. Food and Drug Administration (FDA) is warning that the antipsychotic drug ziprasidone (marketed under the brand name, Geodon, and its generics) is associated with a rare but serious skin...

Johnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to Anti-Multidrug-Resistant Tuberculosis (MDR-TB) Compound

Memorandum of Understanding Signed to Address the Global Health Threat of Antibiotic-Resistant Bacteria NEW BRUNSWICK, N.J., Dec. 11, 2014 /PRNewswire/ -- Johnson & Johnson today announced that...

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS

BOLERO-1 trial explored everolimus in women with HER2+ advanced breast cancer and did not meet criteria for statistical significance in first primary objective[1] The second primary objective...

Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR

Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR DUBLIN, Dec. 11, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that Judge Robert Sweet of the...

Lupin Launches Authorized Generic for Celebrex® Capsules

Lupin Launches Authorized Generic for Celebrex® Capsules Mumbai, Baltimore, December 11, 2014: Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc....

Abbott Completes Acquisition of Veropharm


Health Care Equipment and Supplies Equities Scrutiny - Abbott Laboratories, Zimmer Holdings, Varian Medical Systems, Edwards Lifesciences, and Cerus

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 11, 2014

Statement by Ralph G. Neas, GPhA President and CEO Regarding State Biosimilar Legislation

WASHINGTON, DC (December 9, 2014) — "As state legislatures prepare for their 2015 sessions, I am pleased to announce that GPhA has agreed to support compromise automatic substitution...

Teva Provides 2015 Business Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 11, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2015. In...

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at...

Alexion Pharma (ALXN) Reports Soliris Awarded Orphan Drug Designation in Japan

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW)...

HeartFlow Appoints Former Johnson & Johnson Chairman and CEO William C. Weldon to Board of Directors

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec 10, 2014--HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has named William C. Weldon a new member of its board of...

APAC Joint Replacement Market to Reach $6.4 Billion by 2020

LONDON and NEW YORK, December 10, 2014 /PRNewswire/ --

Prosthetic Heart Valves - Global Trends, Estimates and Forecasts, 2012-2018

DUBLIN, Dec. 10, 2014 /PRNewswire/ --Research and Markets

Mylan Launches One of First Available Generic Versions of Celebrex(R) Capsules

PITTSBURGH, Dec. 10, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic...